Navigation Links
CMC Biologics Announces Appointment of New CEO

COPENHAGEN, Denmark and SEATTLE, May 2, 2011 /PRNewswire/ -- CMC Biologics, a leading biopharmaceutical Contract Manufacturing Organization, with operations in Copenhagen, Denmark and Seattle, Washington USA, announced today that it has hired Claes Glassell to serve at its Chief Executive Officer. CMC Biologics, a company with 370 employees, is committed to delivering  world class, fully integrated, biopharmaceutical process development and manufacturing services.


Claes Glassell brings more than 30 years of industry experience to CMC, most recently as CEO of Cerus Corporation and prior to that as President of Cambrex Corp.

"We are thrilled that Claes has joined the CMC executive team," said David Kauffmann, Chairman of the Board, CMC Biologics, and Managing Director of European Equity Partners. "Claes has been on CMC's board of directors for more than 5 years, and has during that time exhibited a broad range of experience and insight of our industry. Claes' strong leadership qualities and seasoned business understanding makes him the ideal leader to take CMC Biologics to the next level as a leader in our fast moving industry."

"Joining the CMC Executive team at this important time in the Company's lifecycle is a great privilege," said Claes Glassell. "The Company has, despite a very challenging environment in recent years, been successful in continuing to realize strong growth. Today, CMC has a very solid order book demonstrating the strength of the Company's world class service offering, management and science team. CMC is positioned to be a highly successful company."

Claes Glassell joined the CMC board of directors in 2005. Claes left the position as President & CEO of Cerus Corporation, Inc. to take on the position as CEO of CMC Biologics. He is the former President of Cambrex Corporation, Inc. and has previously held senior positions with Akzo Nobel NV, Nobel Industries AB and Berol Kemi AB. His areas of expertise include 20 years of executive positions in publicly listed Life Sciences companies responsible for bioprocessing, active ingredients business, registered therapeutic agents and various support services.

"Having known and worked with Claes for a number of years I am delighted that he has accepted the position as CEO of CMC," said Mads Laustsen, who is leaving the role as CEO of CMC to take up the position as Chief Science Officer responsible for Technology and Corporate Development. Mads will also join the CMC Board of Directors.  "As one of the founders of CMC, I think that Claes brings the best skills and experience to ensure CMC's continued growth. I look forward to working with Claes leading the executive team."

About CMC Biologics

CMC Biologics ( is a leading contract development organization that provides fully integrated biopharmaceutical development and manufacturing services to clients around the world, from its facilities in Europe and the USA. The Company specializes in custom services for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical and in-market API production. CMC Biologics' wide range of integrated services includes cell line development using its proprietary CHEF1®system, process development and best in class comprehensive analytical and characterization services. CMC Biologics has fully segregated microbial and mammalian cell culture suites and offers both stirred tank and perfusion processes. CMC Biologics is located in Copenhagen, Denmark and Bothell, Washington near Seattle, USA.

SOURCE CMC Biologics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
2. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
3. Pioneer® Surgical Technology, Inc. Enters the Biologics Extremities, Trauma, and General Orthopaedics Market with Legato™ Bone Void Filler
4. DSM Biologics Reports a New Record Achievement with DSMs Proprietary XD® Process Technology with a CHO Cell Line Producing an Fc-fusion Protein:
5. MiMedx Completes Acquisition of Surgical Biologics
6. Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011
7. MiMedx Announces Agreement to Acquire Surgical Biologics
8. Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy
9. Reportlinker Adds Global Biosimilars (Follow-on biologics) Market: An Analysis
10. EUSA Pharma Submits ERWINASE(R) Biologics License Application (BLA) for Treatment of Acute Lymphoblastic Leukemia
11. Reportlinker Adds Quality for Biologics
Post Your Comments:
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
Breaking Medicine Technology:
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
Breaking Medicine News(10 mins):